Valuation: Standard BioTools Inc.

Market Cap 292M 257M 242M 221M 413M 28B 416M 2.9B 1.12B 14.25B 1.1B 1.07B 46.37B P/E 2026 *
-7.43x
P/E 2027 * -4.64x
Enterprise Value 292M 257M 242M 221M 413M 28B 416M 2.9B 1.12B 14.25B 1.1B 1.07B 46.37B EV / Sales 2026 *
3.54x
EV / Sales 2027 * 3.55x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Standard BioTools Inc.

1 day+0.13%
1 week+1.78%
Current month+12.80%
1 month+14.31%
3 months-1.33%
6 months-21.78%
Current year-41.95%
1 week 0.73
Extreme 0.7251
0.77
1 month 0.64
Extreme 0.637
0.77
Current year 0.63
Extreme 0.6251
1.67
1 year 0.63
Extreme 0.6251
1.72
3 years 0.63
Extreme 0.6251
3.04
5 years 0.63
Extreme 0.6251
6.66
10 years 0.63
Extreme 0.6251
14.9
Manager TitleAgeSince
Director of Finance/CFO 55 2024-08-31
Chief Executive Officer 63 2021-09-30
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 72 2022-03-31
Director/Board Member 53 2022-04-03
Director/Board Member 63 2021-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Tax

Founder

-28,195 0.0072%
8/20/26 Tax

Executive/Senior Manager

-25,729 0.0066%
8/20/26 Tax

Chief Executive Officer

-97,627 0.0249%
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%+1.78%-43.28%-73.27% 292M
+1.97%+3.05%+44.96%+34.93% 251B
+1.00%+5.30%+20.36%-9.90% 157B
+0.31%+4.17%-10.02%+38.63% 141B
+0.13%+2.59%-54.44%-16.64% 64.75B
-1.26%-2.86%+14.83%+23.07% 49.41B
+1.12%-0.50%-16.17%-20.47% 47.09B
+4.55%+10.55%+38.96%+55.14% 48.73B
+2.31%+0.13%+47.04%+59.96% 42.28B
+7.25%+11.71%+190.12%+106.81% 41.36B
Average +0.44%+3.01%+23.24%+19.82% 84.32B
Weighted average by Cap. -0.05%+3.46%+25.20%+25.35%

Financials

2026 *2027 *
Net sales 82.5M 72.57M 68.41M 62.41M 117M 7.92B 118M 821M 318M 4.03B 310M 303M 13.12B 82.1M 72.22M 68.08M 62.11M 116M 7.88B 117M 817M 317M 4.01B 308M 302M 13.05B
Net income -38.8M -34.13M -32.17M -29.35M -54.89M -3.72B -55.32M -386M -150M -1.9B -146M -143M -6.17B -62.9M -55.33M -52.16M -47.59M -88.99M -6.04B -89.68M -626M -243M -3.07B -236M -231M -10B
Net Debt - -
Logo Standard BioTools Inc.
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Employees
387
Date Price Change Volume
26-09-24 US$0.7430 +0.13% 743,947
26-09-23 US$0.7420 -1.04% 653,426
26-09-22 US$0.7498 +1.06% 1,346,512
26-09-21 US$0.7419 -3.62% 459,594
26-09-18 US$0.7698 +5.45% 2,694,880
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.7430USD
Average target price
1.350USD
Spread / Average Target
+81.70%

Quarterly revenue - Rate of surprise